IFNG and neoplasm: One of the ‘gold’ standards in gauging anti-neoepitope-specific T-cell responses is certainly whether peptide-reactive T-cells – after sorting by tetramers, IFN-γ–capture or by using activation markers (e.g. CD137)-are able to recognize the patient’s own tumor cells.